Identification
- Summary
Calcium glycerophosphate is an medication used to treat low levels of phosphate or calcium, as well as an ingredient in dental products to prevent dental caries.
- Generic Name
- Calcium glycerophosphate
- DrugBank Accession Number
- DB11264
- Background
Calcium glycerophosphate is a Calcium salt of glycerophosphoric acid that forms a white, fine, slightly hygroscopic powder. The commercial product is a mixture of calcium beta-, and D-, and L -alpha-glycerophosphate. By FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings, and fillings. It is also present in dental or oral hygiene products due to its cariostatic effects. It is suggested that calcium glycerophosphate promotes plaque-pH buffering, elevation of plaque Calcium and phosphate levels and direct interaction with dental mineral 2.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Calcium glycerophosphate (DB11264)
- Weight
- Average: 210.135
Monoisotopic: 209.9606158 - Chemical Formula
- C3H7CaO6P
- Synonyms
- 1,2,3-Propanetriol, mono(dihydrogen phosphate) calcium salt
- 1,2,3-Propanetriol, mono(dihydrogen phosphate), calcium salt
- Calcium beta-glycerophosphate
- calcium β-glycerophosphate
- β-glycerophosphoric acid calcium salt
Pharmacology
- Indication
Calcium glycerophosphate is found in OTC dental products such as toothpastes for the prevention of dental caries. As OTC products these do not have an official indication.
In prescription products it is indicated as a Calcium or phosphate donor for replacement or supplementation in patients with insufficient Calcium or phosphate.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
It is thought that calcium glycerophosphate may act through a variety of mechanisms to produce an anti-caries effect 2. These include increasing acid-resistance of the enamel, increasing enamel mineralization, modifying plaque, acting as a pH-buffer in plaque, and elevating Calcium and phosphate levels.
When used as an electrolyte replacement, calcium glycerophosphate donates Calcium and inorganic phosphate. Calcium glycerophosphate is preferable to calcium phosphate due to its increased solubility. Compared to combination calcium gluconate and potassium phosphate, calcium glycerophosphate produces greater phosphate retention which allows for increased Calcium retention and ultimately greater incorporation of the ions into bone structure 1.
- Mechanism of action
Calcium glycerophosphate in combination with sodium monofluorophosphate was found to reduce the acid solubility of enamel. This is thought to be due to increased uptake of fluoride in a non-alkali soluble form at the expense of a fraction remaining in the alkali-soluble form of calcium fluoride 2. It is also thought that calcium glycerophosphate enhances the remineralization effect of sodium monofluorophosphate leading to greater remineralization of enamel but the mechanism behind this is unknown.
Calcium glycerophosphate reduces the decrease in plaque pH produced by sucrose solutions 2. This may be due to the buffering action of donated phosphate which acts as an acceptor to three hydrogen ions to form biphosphate, dihydrogen phosphate, and finally phosphoric acid. As bisphosphate and dihydrogen phosphate are amphoteric, these molecules can act as buffers against both acids and bases.
Studies on plaque-modification by calcium glycerophosphate have been inconsistent 2. Redections in plaque weight and plaque area have been noted in separate studies but neither has been confirmed and no causative link has been established in regards to calcium glycerophosphate's anti-caries effect.
Calcium glycerophosphate donates Calcium and inorganic phosphate resulting in elevated levels of the ions in plaque 2. These ions are important components of the mineral structure of teeth. As such, their presence supports maintenance of healthy tooth structure and mineralization.
In electrolyte replacement calcium glycerophosphate again acts as a donor of Calcium and phosphate. See Calcium Phosphate for pharmacological descriptions of calcium and phosphate.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Alsimine W Vitamins A D Calcium glycerophosphate (13 mg / amp) + Cyanocobalamin (10 mcg / amp) + Dexpanthenol (5 mg / amp) + Dexpanthenol (400 unit / amp) + Ferrous gluconate (16 mg / amp) + Riboflavin-5'-phosphate sodium salt dihydrate (2 mg / amp) + Nicotinamide (40 mg / amp) + Pyridoxine hydrochloride (3 mg / amp) + Thiamine hydrochloride (4.5 mg / amp) + Vitamin A (10000 unit / amp) Capsule; Liquid Oral Alsi Cie Ltee 1978-12-31 2003-05-21 Canada 
Betacol Calcium glycerophosphate (50 mg) + Betaine hydrochloride (61 mg) + Choline bitartrate (2.5 mg) + Potassium bicarbonate (41 mg) Capsule Oral Therapeutic Foods Co. 1989-12-15 1996-09-09 Canada Calcium Inj Calcium glycerophosphate (10 mg) + Calcium levulinate (15 mg) Liquid Intramuscular; Intravenous; Subcutaneous Kripps Pharmacy Ltd. 1981-12-31 Not applicable Canada Dr.chois Toothpaste Step Two Kids Calcium glycerophosphate (0.13 g/100g) + Silicic acid (13.0 g/100g) + Sodium fluoride (0.11 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste, dentifrice Topical Doctor Choi`s Korea Co., LTD. 2022-09-01 Not applicable US 
Formula 2025 Tab Calcium glycerophosphate (34 mg / tab) + Calcium glycerophosphate (51 mg / tab) Tablet Oral Standard Process Inc. Not applicable Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dr.chois Toothpaste Step Two Kids Calcium glycerophosphate (0.13 g/100g) + Silicic acid (13.0 g/100g) + Sodium fluoride (0.11 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste, dentifrice Topical Doctor Choi`s Korea Co., LTD. 2022-09-01 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as glycerophosphates. These are compounds containing a glycerol linked to a phosphate group.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Glycerophospholipids
- Sub Class
- Glycerophosphates
- Direct Parent
- Glycerophosphates
- Alternative Parents
- Alkyl phosphates / Organic calcium salts / Primary alcohols / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic acyclic compound / Alkyl phosphate / Hydrocarbon derivative / Organic calcium salt / Organic oxide / Organic oxygen compound / Organic phosphoric acid derivative / Organic salt / Organooxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- calcium salt (CHEBI:31336)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Y56W30YB7O
- CAS number
- 27214-00-2
- InChI Key
- UHHRFSOMMCWGSO-UHFFFAOYSA-L
- InChI
- InChI=1S/C3H9O6P.Ca/c4-1-3(2-5)9-10(6,7)8;/h3-5H,1-2H2,(H2,6,7,8);/q;+2/p-2
- IUPAC Name
- calcium 2-(phosphonooxy)propane-1,3-diol
- SMILES
- [Ca++].OCC(CO)OP([O-])([O-])=O
References
- General References
- Draper HH, Yuen DE, Whyte RK: Calcium glycerophosphate as a source of calcium and phosphorus in total parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1991 Mar-Apr;15(2):176-80. [Article]
- Lynch RJ: Calcium glycerophosphate and caries: a review of the literature. Int Dent J. 2004;54(5 Suppl 1):310-4. [Article]
- External Links
- KEGG Drug
- D01488
- KEGG Compound
- C12935
- PubChem Substance
- 347911170
- ChemSpider
- 56554
- 1909
- ChEBI
- 31336
- ChEMBL
- CHEMBL3707206
- Wikipedia
- Calcium_glycerophosphate
- MSDS
- Download (46.9 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 1 Completed Prevention Dental Decay 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule; liquid Oral Capsule Oral Liquid Intramuscular; Intravenous; Subcutaneous Paste, dentifrice Topical Tablet Oral Liquid Oral Paste Dental Liquid; tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Decomposes at 170 MSDS water solubility Soluble MSDS - Predicted Properties
Property Value Source Water Solubility 50.9 mg/mL ALOGPS logP -1 ALOGPS logP -2 Chemaxon logS -0.71 ALOGPS pKa (Strongest Acidic) 1.13 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 112.88 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 29.15 m3·mol-1 Chemaxon Polarizability 12.63 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 133.11 predictedDeepCCS 1.0 (2019) [M+H]+ 136.31416 predictedDeepCCS 1.0 (2019) [M+Na]+ 145.58391 predictedDeepCCS 1.0 (2019)
Drug created at December 03, 2015 16:51 / Updated at September 28, 2021 21:54